(H4Z3) HSBC MSCI Emerging Markets - Ratings and Ratios
Equity, Stocks, Emerging, China, India
Description: H4Z3 HSBC MSCI Emerging Markets August 05, 2025
The HSBC MSCI Emerging Markets UCITS ETF USD Acc EUR is an exchange-traded fund listed on XETRA, tracking the Morningstar EM TME NR USD index. It provides investors with exposure to a diversified portfolio of emerging markets equities.
With Assets Under Management (AUM) of approximately €2.637 billion, this ETF is a sizable player in the Global Emerging Markets Equity category. The funds size indicates a reasonable level of liquidity, making it more accessible to investors.
To evaluate the ETFs performance, we can look at key metrics such as tracking error, expense ratio, and dividend yield. Although not directly provided, we can infer that the funds tracking error is likely to be low given its adherence to a well-established index. The expense ratio, a critical KPI, is not specified, but its typically a crucial factor in determining the funds overall cost-effectiveness. A lower expense ratio is generally more desirable as it directly impacts investors net returns.
From a technical analysis perspective, the ETFs price is currently at €11.40, slightly below its 20-day Simple Moving Average (SMA) of €11.45, indicating a potential short-term downward trend. However, its longer-term SMAs (50-day at €11.23 and 200-day at €11.03) suggest an overall upward trend, as the current price is above both. The Average True Range (ATR) of 0.07 (€0.62% of the current price) indicates relatively low volatility, which might be attractive to risk-averse investors.
Considering the ETFs 52-week high and low (€11.67 and €9.45, respectively), the current price is near its 52-week high, suggesting a strong recent performance. Investors should consider this in the context of their overall investment strategy and risk tolerance.
H4Z3 ETF Overview
| Market Cap in USD | 3,040m |
| Category | Global Emerging Markets Equity |
| TER | 0.15% |
| IPO / Inception | 2022-06-28 |
H4Z3 ETF Ratings
| Growth Rating | 73.3% |
| Fundamental | - |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -0.06% |
| Analyst Rating | - |
H4Z3 Dividends
Currently no dividends paidH4Z3 Growth Ratios
| Growth Correlation 3m | 95.8% |
| Growth Correlation 12m | 71.5% |
| Growth Correlation 5y | 83.5% |
| CAGR 5y | 12.92% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.69 |
| CAGR/Mean DD 3y (Pain Ratio) | 3.14 |
| Sharpe Ratio 12m | 0.18 |
| Alpha | 4.59 |
| Beta | 0.000 |
| Volatility | 13.31% |
| Current Volume | 81k |
| Average Volume 20d | 78k |
| Stop Loss | 12.7 (-3.3%) |
| Signal | 0.88 |
What is the price of H4Z3 shares?
Over the past week, the price has changed by -0.47%, over one month by +3.20%, over three months by +13.89% and over the past year by +18.85%.
Is HSBC MSCI Emerging Markets a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of H4Z3 is around 12.78 EUR . This means that H4Z3 is currently overvalued and has a potential downside of -2.67%.
Is H4Z3 a buy, sell or hold?
What are the forecasts/targets for the H4Z3 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 14.3 | 8.5% |
H4Z3 Fundamental Data Overview January 01, 1970
Market Cap EUR = 2.64b (2.64b EUR * 1.0 EUR.EUR)
Beta = 0.0
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 2.64b EUR (2.64b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 2.64b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 2.64b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.48% (E(2.64b)/V(2.64b) * Re(8.48%) + (debt-free company))
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)